ArticleFrontiers in endocrinology2025
Identification and validation of prognostic genes associated with T-cell exhaustion and macrophage polarization in breast cancer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactylation-mediated remodelling of the breast cancer microenvironment: single-cell multidimensional analysis and prognostic model construction.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most frequent malignant tumor in women is breast cancer (BRCA). It has been discovered that T-cell exhaustion and macrophages play significant roles in BRCA. It was necessary to explore prognostic genes associated with T-cell exhaustion and macrophage polarization in BRCA. Methods: The following data were included: 35 macrophage polarization-related genes (MPRGs), 683 T-cell exhaustion-related genes (TEXRGs), GSE20685, as well as TCGA-BRCA. Initially, candidate genes were identified through crossing differentially expressed genes (DEGs) obtained by differential expression analysis, key module genes associated with MPRGs, as well as TEXRGs. Next, 101 combinations of 10 machine learning algorithms and univariate Cox analysis were utilized to screen for prognostic genes. Concurrently, a risk model was built for validation in TCGA-BRCA and GSE20685. Next, we conducted immune infiltration, immunotherapy, mutation analysis, molecular regulatory network, as well as drug sensitivity between the two risk groups. Ultimately, we did the reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Results: According to random survival forest (RSF) algorithm (the best combination with the greatest C-index of 0.799), 7 prognostic genes were selected, which are PGK1, BTG2, TANK, CFB, EIF4E3, TNFRSF18, and BATF. After that, we created a risk model, and in the low-risk samples, there was a relatively high survival rate. Next, between two risk parts, the 7 differential immune cells were found. There was a significant difference in 25 immunological checkpoint (ICI) genes between the two risk parts. Next, a lncRNAs-miRNA-mRNA network with 65 nodes and 70 edges was built. Additionally, 84 medications were shown to differ significantly between the two risk groups. Finally, the expression of BTG2, TANK, and EIF4E3 was verified by RT-PCR, which was consistent with the bioinformatics analysis. Conclusion: The 7 prognostic genes (PGK1, BTG2, TANK, CFB, EIF4E3, TNFRSF18, and BATF) were screened, providing new insights into potential treatments for BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.